40+ years of excellence in custom synthesis and bioconjugation services.
Calculators, design tools, and educational content to support your research.
Custom capped RNA for RNA processing, translation and molecular biology research
Bio-Synthesis supports custom 5′ capped RNA projects with Cap-0 and Cap-1 architectures through project-appropriate chemical synthesis, in vitro transcription (IVT) and enzymatic capping strategies. From short defined RNA fragments to longer transcripts, our team evaluates cap chemistry, sequence constraints, purification and analytical requirements before production.
The 5′ cap is a specialized RNA terminal structure in which a 7-methylguanosine (m⁷G) is linked to the first transcribed nucleotide by an unusual 5′–5′ triphosphate bridge. Cap-0 contains the m⁷G cap; Cap-1 adds a 2′-O-methyl group to the ribose of the first transcribed nucleotide.
For synthetic capped RNA, the desired cap must be matched to the RNA length, 5′ sequence, downstream assay and purification strategy. Short, sequence-defined RNA and longer IVT transcripts may require different manufacturing approaches.
Bio-Synthesis reviews the requested RNA sequence and cap structure to recommend a technically suitable route and an achievable analytical specification.
Conceptual cap architecture, not a complete chemical structure. N₁ = first transcribed nucleotide; ppp = 5′–5′ triphosphate bridge.
The difference is a single ribose methylation at the first transcribed nucleotide, but this modification can affect biological recognition and manufacturing strategy.
7-methylguanosine linked to the first RNA nucleotide through a 5′–5′ triphosphate bridge.
First nucleotide: Unmethylated 2′-OH ribose
Cap-0 architecture with an added 2′-O-methyl group on the first transcribed nucleotide.
Key difference: First-nucleotide 2′-O-methylation
Conceptual structures for comparison, not atom-by-atom chemical drawings. N₁ is the first transcribed nucleotide; ppp denotes the 5′–5′ triphosphate bridge. Cap-1 is distinguished by 2′-O-methylation of N₁.
Important: Cap-0 and Cap-1 are structural definitions, not guarantees of capping efficiency, translation performance or product purity. Cap-1 synthesis may require additional enzymatic or reagent-specific steps.
Select a manufacturing route to review its typical use case, constraints and QC considerations. Final selection is based on the submitted sequence and available chemistry.
ROUTE 01 · SHORT, DEFINED RNA
Potentially useful for shorter RNA constructs requiring precise sequence control, when suitable capped building blocks or coupling chemistry are available.
Route-selection caution: A preferred 5′ starting sequence for IVT is promoter- and transcription-system-dependent. A requirement for a specific 5′ nucleotide can affect transcript initiation, yield and the choice of capping strategy. Chemical capping of longer RNAs may also present purification challenges.
Our technical review considers the complete RNA construct rather than the cap alone.
Cap-0 or Cap-1, cap orientation and 5′ terminal chemistry; other cap analogs evaluated separately.
Short defined RNA fragments or longer IVT products, with attention to first-nucleotide identity and sequence-dependent yield.
Selected modified nucleotides and backbone changes, subject to compatibility with the chosen synthesis and capping route.
Defined 3′ termini, optional poly(A) features and downstream ligation or enzymatic processing requirements.
Chromatographic purity, identity testing, cap incorporation assessment and other agreed analytical endpoints where technically applicable.
Requested amount, concentration, counterion, buffer or dry format, and appropriate handling recommendations.
Evaluate cap-dependent initiation, reporter expression and effects of defined RNA termini.
Study enzymatic cap removal, 5′ end processing and RNA turnover pathways.
Use capped RNA as a defined substrate or process control in decapping and 5′ adapter ligation studies.
Investigate cap-binding proteins, RNA stability and innate immune recognition in defined experimental systems.
Assay design: For workflows involving phosphatase treatment, decapping, adapter ligation, reverse transcription and qPCR, verify that the selected cap and terminal chemistry are compatible with each enzyme step. Functional validation is performed in the customer's assay.
A five-stage project pathway aligns the desired 5′ cap with synthesis feasibility and measurable specifications.
Our project-specific quality approach addresses material traceability, process controls and suitable analytical methods for each capped RNA construct.
Quality-system infrastructure supports custom nucleic acid synthesis, documented specifications and confidential sequence handling.
The availability of individual tests and release criteria depends on RNA length, cap chemistry, analytical method and project scope. ISO systems do not imply that every product is GMP-grade.
General custom RNA production and modified RNA constructs.
Cap chemistry, terminal structures and modification reference.
Longer RNA and mRNA transcription and capping strategies.
IVT RNA production and transcript-specific options.
Additional guidance about 5′ capped oligonucleotides.
Explore integrated oligonucleotide synthesis services.
5′→3′ sequence · cap structure · RNA length · amount · purity · downstream assay · preferred delivery format.
Share the required 5′ nucleotide and experimental workflow. We can evaluate chemical synthesis versus IVT and enzymatic capping before quoting.
Selected background references on RNA cap structures, cap-dependent biological functions and RNA capping approaches.
Note: These publications are provided for scientific background and do not imply use of Bio-Synthesis products. Cap chemistry, incorporation efficiency, RNA length, purification and analytical requirements should be evaluated for each project.
Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.